Roquefort Therapeutics (LON:ROQ) Trading Down 9.1% – Here’s What Happened

Roquefort Therapeutics plc (LON:ROQ) traded down 9.1% on Friday . The company traded as low as GBX 1 and last traded at GBX 1. 162,840 shares changed hands during trading, a decline of 77% from the average session volume of 698,923 shares. The stock had previously closed at GBX 1.10.

Roquefort Therapeutics Stock Performance

The company has a fifty day moving average of GBX 1.26 and a two-hundred day moving average of GBX 1.61. The company has a market cap of £1.64 million, a price-to-earnings ratio of -1.59 and a beta of 0.05. The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79.

Insider Activity

In other Roquefort Therapeutics news, insider Dr Darrin Disley purchased 5,000,000 shares of the stock in a transaction dated Friday, November 21st. The shares were acquired at an average price of GBX 170 per share, for a total transaction of £8,500,000. 22.63% of the stock is owned by insiders.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.